Audioboom logo
Audioboom logo
  • Podcasts
  • Advertisers
  • Creators
  • Help & Support
  • Sign Up
  • Sign In
Podcasts
Advertisers
Creators
Help & Support
Search podcasts
Sign Up
Sign In
Podcast logo
Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity

Jun 25, 2021, 01:26 PM

Facebook Twitter
Headliner
See more options
Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the Wegovy approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version. 
Subscribe
Next
Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
Top Episodes
Tirzepatide for Weight Loss and Lowering HbA1c with Juan Frias, MD
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Podcast logo
Diabetes Dialogue: What to Know about the iLet Bionic Pancreas
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Podcast logo
Diabetes Dialogue: ADCES DTC 22, with Jennifer Okemah, RD, and Gary Scheiner, MS
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
  •   Report this episode
  •   Download audio
  •   QRCode

Sorry, your browser isn't supported by Audioboom.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

Page load failed

Please check your internet connection and refresh the page. You might also try disabling any ad blockers.

You can visit our support center if you're having problems.